Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib in MDS or CMML with Platelet Transfusion Dependence
NCT00109538Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2005
- Primary completion
- Aug 2008
01
Overview
A Phase 3 trial of lonafarnib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Merck & Co.. Started May 2005; status: terminated.
02
Drugs
lonafarnib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00109538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109538.